-
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
-
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
-
Cancer Res Treat. 2018;50(1):195-203. Published online March 21, 2017
-
DOI: https://doi.org/10.4143/crt.2016.376
-
-
 Abstract
 PDF PubReader ePub
- Purpose
Genexol-PM is a biodegradable cremophor EL–free polymeric micelle formulation of paclitaxel. Here,we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment.
Materials and Methods
In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3weeks (6 cycles). The primary endpointwas the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR).
Results
Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ≥ grade 3 occurred in one patient receiving Genexol. All toxicities were manageable.
Conclusion
Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.
-
Citations
Citations to this article as recorded by  - Medical nanoscale materials for virus-induced cervical cancer therapeutic modalities: For targeting delivery
Adane Adugna, Mamaru Getinet, Gashaw Azanaw Amare, Mohammed Jemal
OpenNano.2025; 21: 100221. CrossRef - Nano-drug delivery systems based on biodegradable polymers for the therapy of gynecological malignancies
Keer Jin, Hanxue Zhang, Yuwei Yang, Yan Gao
International Journal of Polymeric Materials and Polymeric Biomaterials.2024; 73(14): 1262. CrossRef - Dual stimuli-responsive polymeric prodrug consisting of reversible covalent bonded celastrol for tumor targeted delivery
Jiangtao Su, Meng Rao, Heshuang Dai, Le Cai, Fan Ye, Lu Ye, Yuchen Hu, Ban Chen, Xiaoxia Guo
Macromolecular Research.2024; 32(2): 173. CrossRef - Designing nanodiscs as versatile platforms for on-demand therapy
Qianwen Mu, Haolan Deng, Xiaoyu An, Gang Liu, Chao Liu
Nanoscale.2024; 16(5): 2220. CrossRef - Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
Journal of Oncology Pharmacy Practice.2024; 30(2): 367. CrossRef - Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond
Yalan Zhu, Lingling Xu, Yong Kang, Qinzhen Cheng, Yiling He, Xiaoyuan Ji
Biomaterials.2024; 306: 122478. CrossRef - Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion
Fei Li, Yahong Wang, Dandan Chen, Yunjie Du
International Journal of Molecular Sciences.2024; 25(3): 1396. CrossRef - Delivery of Nucleic Acid Drugs for Tumor Therapy: Opportunities and Challenges
Dandan Sun, Wenjia Tan, Jianan Zhao, Yafei Tian, Siqi Li, Zhiqi Zhang, Xinzhe Dong, Xiaonan Liu, Na Liu, Ping Jiao, Jie Ma
Fundamental Research.2024;[Epub] CrossRef - Effect of high-dose polymeric nanoparticle micellar paclitaxel on improved progression-free survival in patients with optimally resected stage III or IV high-grade carcinoma of the ovary: a prospective cohort study with historical controls
Soo Jin Park, Joo-Hyuk Son, Tae-Wook Kong, Suk-Joon Chang, Hee Seung Kim
Frontiers in Oncology.2024;[Epub] CrossRef - Co-Assembly of Cancer Drugs with Cyclo-HH Peptides: Insights from Simulations and Experiments
Anastasia Vlachou, Vijay Bhooshan Kumar, Om Shanker Tiwari, Sigal Rencus-Lazar, Yu Chen, Busra Ozguney, Ehud Gazit, Phanourios Tamamis
ACS Applied Bio Materials.2024; 7(4): 2309. CrossRef - Biomarkers in Ovarian Cancer: Towards Personalized Medicine
Carlos López-Portugués, María Montes-Bayón, Paula Díez
Proteomes.2024; 12(1): 8. CrossRef - Internalization of transferrin-tagged Myxococcus xanthus encapsulins into mesenchymal stem cells
Anna N. Gabashvili, Natalya A. Alexandrushkina, Elizaveta N. Mochalova, Daria V. Goliusova, Ekaterina N. Sapozhnikova, Pavel I. Makarevich, Petr I. Nikitin
Experimental Biology and Medicine.2024;[Epub] CrossRef - Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
Ana Serras, Célia Faustino, Lídia Pinheiro
Pharmaceutics.2024; 16(8): 1047. CrossRef - Polyesters and Polyester Nano- and Microcarriers for Drug Delivery
Stanislaw Slomkowski, Teresa Basinska, Mariusz Gadzinowski, Damian Mickiewicz
Polymers.2024; 16(17): 2503. CrossRef - Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics
Mahua Sarkar, Yang Wang, Oscar Ekpenyong, Dong Liang, Huan Xie
WIREs Nanomedicine and Nanobiotechnology.2023;[Epub] CrossRef - Cancer treatment and toxicity outlook of nanoparticles
Neetika, Mamta Sharma, Pankaj Thakur, Paras Gaur, Gokana Mohana Rani, Sarvesh Rustagi, Rishi Kumar Talreja, Vishal Chaudhary
Environmental Research.2023; 237: 116870. CrossRef - Efficacy and Safety of Nanopaclitaxel Formulation for Cancer Treatment: Evidence From Randomized Clinical Trials
Xiangmin Deng, Xiaoqin Huang, Xiaoyan Dong, Genxiang Mao, Wenmin Xing
Nanomedicine.2023; 18(10): 833. CrossRef - Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers
Tetiana Korzun, Abraham S. Moses, Parham Diba, Ariana L. Sattler, Brennan Olson, Olena R. Taratula, Tanja Pejovic, Daniel L. Marks, Oleh Taratula
Small.2023;[Epub] CrossRef - Nanoprobe-based molecular imaging for tumor stratification
Xianbin Ma, Mingchuan Mao, Jiaqi He, Chao Liang, Hai-Yan Xie
Chemical Society Reviews.2023; 52(18): 6447. CrossRef - Magic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles
Bakr Ahmed, Anuradha Sharma, Zakiya Usmani, Garima Sharma, Joga Singh, Radhika Yadav, Indu Sharma, Indu Pal Kaur
Journal of Drug Delivery Science and Technology.2023; 88: 104945. CrossRef - Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study
So Hyun Nam, Shin-Wha Lee, Young-Jae Lee, Yong Man Kim
Cancer Research and Treatment.2023; 55(4): 1346. CrossRef - Effective Cancer Management: Inimitable Role of Phytochemical Based Nano-
Formulations
Aman Upaganlawar, Satish Polshettiwar, Sushil Raut, Amol Tagalpallewar, Vishal Pande
Current Drug Metabolism.2022; 23(11): 869. CrossRef - Comparison of triblock copolymeric micelles based on α- and ε-poly(L-lysine): a Cornelian choice
Franck Marquet, Viorica Patrulea, Gerrit Borchard
Polymer Journal.2022; 54(2): 199. CrossRef - Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic
Vladimir A. Ljubimov, Arshia Ramesh, Saya Davani, Moise Danielpour, Joshua J. Breunig, Keith L. Black
Advanced Drug Delivery Reviews.2022; 181: 114033. CrossRef - Nanocarriers targeting the diseases of the pancreas
Nurbanu Demirtürk, Erem Bilensoy
European Journal of Pharmaceutics and Biopharmaceutics.2022; 170: 10. CrossRef - The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
Xiaokun Li, Lingmin Chen, Siyuan Luan, Jianfeng Zhou, Xin Xiao, Yushang Yang, Chengyi Mao, Pinhao Fang, Longqi Chen, Xiaoxi Zeng, Huile Gao, Yong Yuan
Seminars in Cancer Biology.2022; 86: 873. CrossRef - Beyond separation: Membranes towards medicine
Ying Xie, Zhenyu Chu, Wanqin Jin
Journal of Membrane Science Letters.2022; 2(1): 100020. CrossRef - Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy
Sajad Fakhri, Seyed Zachariah Moradi, Akram Yarmohammadi, Fatemeh Narimani, Carly E. Wallace, Anupam Bishayee
Frontiers in Oncology.2022;[Epub] CrossRef - Gold Nanorods for Drug and Gene Delivery: An Overview of Recent Advancements
Atieh Jahangiri-Manesh, Marziyeh Mousazadeh, Shirinsadat Taji, Abbas Bahmani, Atefeh Zarepour, Ali Zarrabi, Esmaeel Sharifi, Mostafa Azimzadeh
Pharmaceutics.2022; 14(3): 664. CrossRef - Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
Ekati Drakopoulou, Nicholas P. Anagnou, Kalliopi I. Pappa
Cancers.2022; 14(13): 3238. CrossRef - Engineering nanosystems to overcome barriers to cancer diagnosis and treatment
Suhaila O. Alhaj-Suliman, Emad I. Wafa, Aliasger K. Salem
Advanced Drug Delivery Reviews.2022; 189: 114482. CrossRef - Metabolic Signatures of Surface-Modified Poly(lactic-co-glycolic acid) Nanoparticles in Differentiated THP-1 Cells Derived with Liquid Chromatography-Mass Spectrometry-based Metabolomics
Mohammad A. Al-natour, Salah Abdelrazig, Amir M. Ghaemmaghami, Cameron Alexander, Dong-Hyun Kim
ACS Omega.2022; 7(33): 28806. CrossRef - Pathogen-derived peptides in drug targeting and its therapeutic approach
Seok-Jun Mun, Euni Cho, Jae-Sung Kim, Chul-Su Yang
Journal of Controlled Release.2022; 350: 716. CrossRef - Application of single and cooperative different delivery systems for the treatment of intervertebral disc degeneration
Zongtai Liu, Changfeng Fu
Frontiers in Bioengineering and Biotechnology.2022;[Epub] CrossRef - Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions
Koustav Pal, Rahul A. Sheth
Cancers.2022; 15(1): 196. CrossRef - Nanoparticle delivery systems to combat drug resistance in ovarian cancer
Emily M. Miller, Timothy M. Samec, Angela A. Alexander-Bryant
Nanomedicine: Nanotechnology, Biology and Medicine.2021; 31: 102309. CrossRef - Engineering precision nanoparticles for drug delivery
Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas, Robert Langer
Nature Reviews Drug Discovery.2021; 20(2): 101. CrossRef - Clinical applications of nanomedicines in lung cancer treatment
Mohammad Norouzi, Pierre Hardy
Acta Biomaterialia.2021; 121: 134. CrossRef - Lyophilization stabilizes clinical‐stage core‐crosslinked polymeric micelles to overcome cold chain supply challenges
Tarun Ojha, Qizhi Hu, Claudio Colombo, Jan Wit, Michiel van Geijn, Mies J. van Steenbergen, Mahsa Bagheri, Hiltrud Königs‐Werner, Eva Miriam Buhl, Ruchi Bansal, Yang Shi, Wim E. Hennink, Gert Storm, Cristianne J. F. Rijcken, Twan Lammers
Biotechnology Journal.2021;[Epub] CrossRef - Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface
Shannon R. Tracey, Peter Smyth, Caroline J. Barelle, Christopher J. Scott
Biochemical Society Transactions.2021; 49(5): 2253. CrossRef - Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef - Engineering Considerations to Produce Bioactive Compounds from Plant Cell Suspension Culture in Bioreactors
Elizabeth Alejandra Motolinía-Alcántara, Carlos Omar Castillo-Araiza, Mario Rodríguez-Monroy, Angélica Román-Guerrero, Francisco Cruz-Sosa
Plants.2021; 10(12): 2762. CrossRef - Clinical applications of nanomedicine in cancer therapy
Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian, Fatemeh Atyabi
Drug Discovery Today.2020; 25(1): 107. CrossRef - Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products
April L. Risinger, Lin Du
Natural Product Reports.2020; 37(5): 634. CrossRef Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis
Pi-Ling Chou, Ya-Ping Huang, Meng-Hsuan Cheng, Kun-Ming Rau, Yi-Ping Fang
International Journal of Nanomedicine.2020; Volume 15: 1731. CrossRef- Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval
Duhyeong Hwang, Jacob D. Ramsey, Alexander V. Kabanov
Advanced Drug Delivery Reviews.2020; 156: 80. CrossRef - Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
Yuan Li, Yan Gao, Xi Zhang, Hongyan Guo, Huile Gao
International Journal of Pharmaceutics.2020; 591: 119986. CrossRef - Synthesis of PCL–PEG–PCL Triblock Copolymer via Organocatalytic Ring-Opening Polymerization and Its Application as an Injectable Hydrogel—An Interdisciplinary Learning Trial
Kaiting Wu, Lin Yu, Jiandong Ding
Journal of Chemical Education.2020; 97(11): 4158. CrossRef Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use
Madhusmita Dhupal, Devasish Chowdhury
International Journal of Nanomedicine.2020; Volume 15: 9125. CrossRef- Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance
Yuxuan Dai, Xingguang Cai, Xinzhou Bi, Chunxia Liu, Na Yue, Ying Zhu, Jiaqi Zhou, Mian Fu, Wenlong Huang, Hai Qian
European Journal of Medicinal Chemistry.2019; 171: 104. CrossRef - A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
The Oncologist.2019; 24(6): 751. CrossRef - Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging
Xiaoxue Xie, Yu Chen, Zhongyuan Chen, Yi Feng, Jing Wang, Tingting Li, Shun Li, Xiang Qin, Chunhui Wu, Chuan Zheng, Jie Zhu, Fengming You, Yiyao Liu, Hong Yang
ACS Applied Materials & Interfaces.2019; 11(47): 43865. CrossRef - Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
A. G. Kedrova, S. E. Krasilnikov, D. A. Astakhov, V. V. Kosyy
Tumors of female reproductive system.2019; 15(3): 37. CrossRef - Improving Drug Delivery of Micellar Paclitaxel against Non‐Small Cell Lung Cancer by Coloading Itraconazole as a Micelle Stabilizer and a Tumor Vascular Manipulator
Ling Zhang, Zhengsheng Liu, Chao Kong, Chun Liu, Kuan Yang, Huijun Chen, Jinfeng Huang, Feng Qian
Small.2018;[Epub] CrossRef
-
13,147
View
-
353
Download
-
57
Web of Science
-
54
Crossref
-
Uterine Leiomyosarcoma : 14-year Two-center Experience of 31 Cases
-
Woo Young Kim, Suk-Joon Chang, Ki-Hong Chang, Jong-Hyuck Yoon, Jang Hee Kim, Byoung-Gie Kim, Duk-Soo Bae, Hee-Sug Ryu
-
Cancer Res Treat. 2009;41(1):24-28. Published online March 31, 2009
-
DOI: https://doi.org/10.4143/crt.2009.41.1.24
-
-
Abstract
PDFPubReaderePub
- Purpose
The aim of this study was to evaluate the clinicopathological characteristics of uterine leiomyosarcoma (LMS) and possible prognostic factors. Materials and MethodsThis study included 31 patients with histologically proven LMS at Samsung Medical Center and Ajou University Hospital between 1994 and 2007. The medical records and available histological slides were reviewed retrospectively. ResultsThe median age was 46 years (range, 32~63). The most common symptom was vaginal bleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III, seven patients with stage IV disease. The median follow up time was 29 months (range, 1~94). The most common recurrence site was lung (5 case), followed by pelvis and upper abdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%. Early tumor stage and mitotic count were the prognostic factor in univariate analysis (p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated with prognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stage disease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF) had a trend for disease recurrence in early stage LMS (p=0.0859). ConclusionMitotic count less than 15/HPF in early stage may be related with longer progression-free interval, but we could not reach the conclusion that adjuvant therapy in early stage LMS be effective.
-
Citations
Citations to this article as recorded by - 2‑D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells
Hosouk Joung, Hyunju Liu
Oncology Reports.2024;[Epub] CrossRef - Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee
Clinical Cancer Research.2022; 28(17): 3850. CrossRef - Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature
Bruna Cristine de Almeida, Laura Gonzalez dos Anjos, Andrey Senos Dobroff, Edmund Chada Baracat, Qiwei Yang, Ayman Al-Hendy, Katia Candido Carvalho
Biomedicines.2022; 10(10): 2567. CrossRef - Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis
Alessandro Rizzo, Margherita Nannini, Annalisa Astolfi, Valentina Indio, Pierandrea De Iaco, Anna Myriam Perrone, Antonio De Leo, Lorena Incorvaia, Valerio Di Scioscio, Maria Abbondanza Pantaleo
Cancers.2020; 12(7): 1899. CrossRef - Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage
Dhara Patel, Elizabeth Handorf, Margaret von Mehren, Lainie Martin, Sujana Movva
Sarcoma.2019; 2019: 1. CrossRef - Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases
E Sun Paik, Jae Hong Kang, Jihye Kim, Yeon-Joo Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee
Obstetrics & Gynecology Science.2019; 62(2): 103. CrossRef - Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis
Su Hyun Chae, Seung-Hyuk Shim, Misoo Chang, Ah Young Choi, Gun Gu Kang, Sun Joo Lee, Soo-Nyung Kim
Gynecologic Oncology.2019; 154(3): 638. CrossRef - Clinicopathological Correlation of Uterine Corpus Tumors: A Study of 433 Cases
Divya Shekhar Shetty, Alka Vikas Gosavi, Prashant Shankarrao Murarkar, Kalpana Ranjitsingh Sulhyan
Indian Journal of Gynecologic Oncology.2019;[Epub] CrossRef - Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis
Giorgio Bogani, Giovanni Fucà, Giuseppa Maltese, Antonino Ditto, Fabio Martinelli, Mauro Signorelli, Valentina Chiappa, Cono Scaffa, Ilaria sabatucci, Francesca Lecce, Francesco Raspagliesi, Domenica Lorusso
Gynecologic Oncology.2016; 143(2): 443. CrossRef - Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation
Jasmine Tan-Kim, Katherine A. Hartzell, Caryl S. Reinsch, Cristina H. O’Day, John S. Kennedy, Shawn A. Menefee, Terry A. Harrison
American Journal of Obstetrics and Gynecology.2015; 212(5): 594.e1. CrossRef - Successful removal of uterine leiomyosarcoma tumour thrombus propagating to the right atrium
Yu Hui Lim, Lui Shiong Lee, Chong Hee Lim, Ghee Kheng Chew
BMJ Case Reports.2015; : bcr2015213384. CrossRef - Lung Metastasis after an Eighteen-Years-Long Disease-Free Period since Uterine Leiomyosarcoma Diagnosis
M. Guazzaroni, D. Tosti, M. Rascioni, M. Mataloni, D. Citraro, G. Simonetti
Case Reports in Oncological Medicine.2014; 2014: 1. CrossRef - FIGO Staging for Uterine Sarcomas: Can the Revised 2008 Staging System Predict Survival Outcome Better?
Ga Won Yim, Eun Ji Nam, Sang Wun Kim, Young Tae Kim
Yonsei Medical Journal.2014; 55(3): 563. CrossRef - Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma
Philip Wong, Kathy Han, Jenna Sykes, Charles Catton, Stephane Laframboise, Anthony Fyles, Lee Manchul, Wilfred Levin, Michael Milosevic
Radiation Oncology.2013;[Epub] CrossRef - Uterine Sarcomas: Then and Now
Shaan H. Shah, Jyothi P. Jagannathan, Katherine Krajewski, Kevin N. O???Regan, Suzanne George, Nikhil H. Ramaiya
American Journal of Roentgenology.2012; 199(1): 213. CrossRef - Prognostic Factors and Outcomes in 28 Cases of Uterine Leiomyosarcoma
V. Loizzi, G. Cormio, D. Nestola, M. Falagario, A. Surgo, A. Camporeale, G. Putignano, L. Selvaggi
Oncology.2011; 81(2): 91. CrossRef - Surgical treatment of uterine sarcoma
Joo-Hyun Nam
Best Practice & Research Clinical Obstetrics & Gynaecology.2011; 25(6): 751. CrossRef - The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma
Jeong-Yeol Park, Sun-Kyung Park, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
Gynecologic Oncology.2011; 122(2): 255. CrossRef - Co-existence of three rare gynecological tumors in a 79-year-old woman
Hongkai Zhang, Melinda Lerwill
Archives of Gynecology and Obstetrics.2011; 284(3): 695. CrossRef
-
10,483
View
-
61
Download
-
19
Crossref
-
Relationship between Pre-treatment Serum SCC (squamous cell carcinoma) Antigen, Cyfra 21-1 Levels, and Survival in Squamous Cell Carcinoma of the Uterine Cervix
-
Ki-Hong Chang, Hee-Sug Ryu, Suk-Joon Chang, Young-Ji Byun, Jung-Pil Lee
-
Cancer Res Treat. 2005;37(5):302-306. Published online October 31, 2005
-
DOI: https://doi.org/10.4143/crt.2005.37.5.302
-
-
Abstract
PDFPubReaderePub
- Purpose
To determine the relationship between pretreatment serum squamous cell carcinoma (SCC) antigen and Cyfra 21-1 levels, and survival in patients with invasive squamous cell carcinoma of the cervix. Materials and MethodsOne hundred and one cervical squamous cell carcinoma patients were included. Pre-treatment levels of serum SCC antigen and Cyfra 21-1 were measured, with a 5 year minimum follow up. Thirty two recurrent disease (RD) patients were compared to 99 non-recurrent disease (NRD) patients with respect to tumor markers, FIGO stage, lesion size, lymph node status, and parametrial involvement. ResultsPre-treatment serum SCC antigen and Cyfra 21-1 levels were significantly higher in the RD group (p<0.001). Combined serum SCC antigen and Cyfra 21-1 levels showed higher sensitivity for prediction of recurrence (90.6%). Pre-treatment SCC antigen and Cyfra 21-1 levels showed correlation with high FIGO stage, large lesion size, lymph node status, and parametrial involvement (p<0.001). Normal pre-treatment levels of SCC antigen and Cyfra 21-1 showed a 5-year survival rate of 93% and 90% respectively, while elevated levels showed significantly decreased survival rate of 63% and 59%, respectively (p<0.001). Odd ratio for cumulative survival rates were 6.87 for SCC antigen, and 5.07 for Cyfra 21-1 (p<0.001). ConclusionInitial pre-treatment levels of serum SCC antigen and Cyfra 21-1 are closely related to FIGO stage, lesion size, lymph node and parametrial involvement in patients with squamous cell carcinoma of the cervix. Also, these markers may be of help to predicting recurrent disease and survival rates.
|
KCA
